PMID- 21787451
OWN - NLM
STAT- MEDLINE
DCOM- 20120413
LR  - 20120209
IS  - 1475-2662 (Electronic)
IS  - 0007-1145 (Linking)
VI  - 107
IP  - 5
DP  - 2012 Mar
TI  - Protective effects of fractional extracts from Panellus serotinus on 
      non-alcoholic fatty liver disease in obese, diabetic db/db mice.
PG  - 639-46
LID - 10.1017/S0007114511003485 [doi]
AB  - Non-alcoholic fatty liver disease (NAFLD) is emerging as the most common liver 
      disease in industrialised countries. Various mushrooms have been used in Eastern 
      folk medicine for the treatment of lifestyle diseases. We previously found that 
      the dietary intake of powdered whole Panellus serotinus (Mukitake) alleviates 
      NAFLD in obese, diabetic db/db mice. In the present study, we investigated the 
      influence of Mukitake fractional extracts on the development of NAFLD in db/db 
      mice. A significant reduction in the hepatic TAG content, macrovesicular 
      hepatocytes and activities of key enzymes for de novo synthesis of the fatty acid 
      was observed in both the water-soluble Mukitake extract (WE) diet and the 
      ethanol-soluble Mukitake extract (EE) diet groups compared with the control diet 
      group of the db/db mice. The serum level of monocyte chemoattractant protein-1 
      (MCP-1), which is known to exacerbate insulin resistance, was significantly 
      decreased in the WE group. On the other hand, the serum level of adiponectin, 
      which plays a protective role against the metabolic syndrome, was significantly 
      increased in the EE group. Additionally, differential analysis between Mukitake 
      and Shiitake, mycelia from the same family, using liquid chromatography 
      time-of-flight MS technology revealed that only seven and five compounds exist in 
      WE and EE from Mukitake, respectively. In conclusion, the present study 
      demonstrated that Mukitake displays at least two different physiological actions 
      that alleviate NAFLD: one through the reduction in inflammatory damage by its 
      suppression in MCP-1 production and the other through an increase in level of 
      serum adiponectin and the prevention of visceral fat accumulation.
FAU - Inafuku, Masashi
AU  - Inafuku M
AD  - Department of Applied Biochemistry and Food Science, Saga University, Saga 
      840-8502, Japan.
FAU - Nagao, Koji
AU  - Nagao K
FAU - Nomura, Saori
AU  - Nomura S
FAU - Shirouchi, Bungo
AU  - Shirouchi B
FAU - Inoue, Nao
AU  - Inoue N
FAU - Nagamori, Naoki
AU  - Nagamori N
FAU - Nakayama, Hideyuki
AU  - Nakayama H
FAU - Toda, Takayoshi
AU  - Toda T
FAU - Yanagita, Teruyoshi
AU  - Yanagita T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110726
PL  - England
TA  - Br J Nutr
JT  - The British journal of nutrition
JID - 0372547
RN  - 0 (Adiponectin)
RN  - 0 (Adipoq protein, mouse)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Ccl2 protein, mouse)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (RNA, Messenger)
RN  - 0 (Triglycerides)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adiponectin/blood
MH  - Agaricales/*chemistry
MH  - Animals
MH  - Anti-Inflammatory Agents/chemistry/therapeutic use
MH  - Anti-Obesity Agents/chemistry/*therapeutic use
MH  - Chemokine CCL2/blood/genetics
MH  - Diabetes Mellitus, Type 2/complications/metabolism/pathology/*prevention & 
      control
MH  - Fatty Liver/complications/metabolism/pathology/*prevention & control
MH  - Gene Expression Regulation/drug effects
MH  - Hypoglycemic Agents/chemistry/*therapeutic use
MH  - Intra-Abdominal Fat/drug effects/immunology/metabolism/pathology
MH  - Liver/drug effects/immunology/metabolism/pathology
MH  - Male
MH  - *Medicine, East Asian Traditional
MH  - Mice
MH  - Mice, Mutant Strains
MH  - Obesity/complications/metabolism/pathology/*prevention & control
MH  - RNA, Messenger/metabolism
MH  - Random Allocation
MH  - Solubility
MH  - Triglycerides/metabolism
MH  - Tumor Necrosis Factor-alpha/genetics/metabolism
EDAT- 2011/07/27 06:00
MHDA- 2012/04/14 06:00
CRDT- 2011/07/27 06:00
PHST- 2011/07/27 06:00 [entrez]
PHST- 2011/07/27 06:00 [pubmed]
PHST- 2012/04/14 06:00 [medline]
AID - S0007114511003485 [pii]
AID - 10.1017/S0007114511003485 [doi]
PST - ppublish
SO  - Br J Nutr. 2012 Mar;107(5):639-46. doi: 10.1017/S0007114511003485. Epub 2011 Jul 
      26.